https://www.selleckchem.com/pr....oducts/cl-amidine.ht
Hepatocellular carcinoma (HCC) surveillance rates are suboptimal in clinical practice. We aimed to elicit providers' opinions on the following aspects of HCC surveillance preferred strategies, barriers and facilitators, and the impact of a patient's HCC risk on the choice of surveillance modality. We conducted a web-based survey among gastroenterology and hepatology providers (40% faculty physicians, 21% advanced practice providers, 39% fellow-trainees) from 26 U.S. medical centers in 17 states. Of 654 eligible providers, 305 (47%) c